IDH2 and acute myeloid leukemia: We performed a comprehensive analysis of the efficacy of two IDH inhibitor regimens (IDH inhibitor combination and IDH inhibitor alone) in two populations (newly diagnosed IDH-mutated AML patients and R/R IDH-mutated AML patients) based on treatment response and survival.